Pixantrone Dimaleate

匹杉琼二马来酸盐

Report date: 2026/03/26 15:11:53
NME

Base Information

Drug NamePixantrone Dimaleate
Drug Alias Namepixantronum匹杉琼二马来酸盐pixantrone匹杉琼匹杉琼马来酸盐pixantrona +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA intercalatorsTopoisomerase II inhibitors
TargetsTopoisomerase IIDNA
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisBreast Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[32] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCell Therapy Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJohannes Gutenberg-University MainzAarhus UniversityLes Laboratoires Servier
Inactive CompaniesTheradexCti Biopharma CorpNational Cancer Institute
Active IndicationsLymphoma, Non-HodgkinLymphoma
Inactive IndicationsSolid tumoursNeoplasm MetastasisBreast Neoplasms +[9] 

Other Information

ATC CodeL01DB11
Related LinksWikipediaDrugBankKEGG